All In Biotech

Drug Trial Radar · NCT03301168

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

Last checked: Nov 19, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 2014

Primary completion

May 11, 2021

Study completion May 2034

Sponsor

Lead sponsor
Bellicum PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 26 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).

Conditions

  • Acute Lymphoblastic Leukemia
  • Leukemia, Acute Myeloid (AML), Child
  • Lymphoma, Non-Hodgkin
  • Myelodysplastic Syndromes
  • Primary Immune Deficiency Disorder
  • Osteopetrosis
  • Cytopenia
  • Hemoglobinopathy in Children
  • Anemia, Aplastic

Interventions

  • BPX-501 T cellsBiological

    T cells transduced with CaspaCIDe® safety switch

  • RimiducidDrug

    administered to inactivate BPX-501 cells in the event of GVHD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventTime frame: Month 24
  2. TRM/NRMTime frame: Day 180, Month 12

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Stanford University - Division of Pediatric Stem Cell Transplant & Regenerative Medicine

    Palo Alto, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Dana-Farber Boston Children's Cancer and Blood Disorders Center

    Boston, Massachusetts

  • Children's Hospital at Montefiore

    The Bronx, New York

  • Oregon Health Sciences University - Doernbecher Children's Hospital

    Portland, Oregon

  • University of Texas Southwestern-Children's Medical Center

    Dallas, Texas

  • Baylor College of Medicine/ Texas Children's Hospital

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.